Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 55 entries
Sorted by: Best Match Show Resources per page
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 15148527
Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity(R), the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004;26(3):211-44
Bayés, M., Rabasseda, X., & Prous, J. R. (2004). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 26(3), 211-44.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 26,3 (2004): 211-44.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44. PMID: 15148527.
Copy Download .nbib Format: NLM
Ziconotide (Elan Pharmaceuticals).

IDrugs : the investigational drugs journal

Heading CE.
PMID: 16025393
IDrugs. 2001 Mar;4(3):339-50.

UNLABELLED: Elan Pharmaceuticals (formerly Neurex) is developing ziconotide, a neuron-specific N-type calcium channel blocker, for the potential treatment of severe pain and ischemia. A US NDA for the use of the compound in intractable pain is under review [351606,357600]...

Cite
Heading CE. Ziconotide (Elan Pharmaceuticals). IDrugs. 2001;4(3):339-50
Heading, C. E. (2001). Ziconotide (Elan Pharmaceuticals). IDrugs : the investigational drugs journal, 4(3), 339-50.
Heading, C E. "Ziconotide (Elan Pharmaceuticals)." IDrugs : the investigational drugs journal vol. 4,3 (2001): 339-50.
Heading CE. Ziconotide (Elan Pharmaceuticals). IDrugs. 2001 Mar;4(3):339-50. PMID: 16025393.
Copy Download .nbib Format: NLM
Gateways to clinical trials. July-August 2008.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 18850047
Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95.

(-)-Epigallocatechin gallate, 501516, 89-12; Abatacept, Adalimumab, Adefovir dipivoxil, AG-701, Agatolimod sodium, Alefacept, Aliskiren fumarate, Apixaban, Atazanavir sulfate, Atrasentan, Axitinib; BI-1744-CL, BIBF-1120, BIBW-2992, Bortezomib; Carboxyamidotriazole, Caspofungin acetate, CBP-501, Cediranib, Ceftobiprole, Certolizumab pegol, Cetuximab, Cholesteryl hydrophobized polysaccharide-Her2 protein complex, CHP-NY-ESO-1, Cypher;...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008;30(6):459-95
Tomillero, A., & Moral, M. A. (2008). Gateways to clinical trials. July-August 2008. Methods and findings in experimental and clinical pharmacology, 30(6), 459-95.
Tomillero, A, and Moral, M A. "Gateways to clinical trials. July-August 2008." Methods and findings in experimental and clinical pharmacology vol. 30,6 (2008): 459-95.
Tomillero A, Moral MA. Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95. PMID: 18850047.
Copy Download .nbib Format: NLM
Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration.

Neuromodulation : journal of the International Neuromodulation Society

Shields D, Montenegro R, Aclan J.
PMID: 22150947
Neuromodulation. 2007 Oct;10:12-7. doi: 10.1111/j.1525-1403.2007.00132.x.

Objective.  To determine the stability of admixtures combining ziconotide with commercially formulated or powdered baclofen during simulated intrathecal infusion under laboratory conditions at 37°. Materials and Methods.  Admixtures of ziconotide (25 µg/mL) with commercially formulated (1.5 mg/mL) or powdered...

Cite
Shields D, Montenegro R, Aclan J. Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. Neuromodulation. 2007;10:12-7doi: 10.1111/j.1525-1403.2007.00132.x.
Shields, D., Montenegro, R., & Aclan, J. (2007). Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. Neuromodulation : journal of the International Neuromodulation Society, 1012-7. https://doi.org/10.1111/j.1525-1403.2007.00132.x
Shields, David, et al. "Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration." Neuromodulation : journal of the International Neuromodulation Society vol. 10 (2007): 12-7. doi: https://doi.org/10.1111/j.1525-1403.2007.00132.x
Shields D, Montenegro R, Aclan J. Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. Neuromodulation. 2007 Oct;10:12-7. doi: 10.1111/j.1525-1403.2007.00132.x. PMID: 22150947.
Copy Download .nbib Format: NLM
Ziconotide-induced psychosis: A case report and literature review.

The mental health clinician

Burdge G, Leach H, Walsh K.
PMID: 30206508
Ment Health Clin. 2018 Aug 30;8(5):242-246. doi: 10.9740/mhc.2018.09.242. eCollection 2018 Sep.

Ziconotide is an intrathecally administered medication indicated for the treatment of severe chronic pain in patients who are intolerant of or refractory to other treatment options. A black box warning is included in the packaging and states ziconotide is...

Cite
Burdge G, Leach H, Walsh K. Ziconotide-induced psychosis: A case report and literature review. Ment Health Clin. 2018;8(5):242-246doi: 10.9740/mhc.2018.09.242.
Burdge, G., Leach, H., & Walsh, K. (2018). Ziconotide-induced psychosis: A case report and literature review. The mental health clinician, 8(5), 242-246. https://doi.org/10.9740/mhc.2018.09.242
Burdge, Gary, et al. "Ziconotide-induced psychosis: A case report and literature review." The mental health clinician vol. 8,5 (2018): 242-246. doi: https://doi.org/10.9740/mhc.2018.09.242
Burdge G, Leach H, Walsh K. Ziconotide-induced psychosis: A case report and literature review. Ment Health Clin. 2018 Aug 30;8(5):242-246. doi: 10.9740/mhc.2018.09.242. eCollection 2018 Sep. PMID: 30206508; PMCID: PMC6125118.
Copy Download .nbib Format: NLM
Near-resolution of persistent idiopathic facial pain with low-dose lumbar intrathecal ziconotide: a case report.

Journal of pain research

Staub BP, Casini GP, Monaco EA, Sekula RF, Emerick TD.
PMID: 30881103
J Pain Res. 2019 Mar 08;12:945-949. doi: 10.2147/JPR.S193746. eCollection 2019.

PURPOSE: Persistent idiopathic facial pain (PIFP) is a poorly defined and debilitating chronic pain state with a challenging and often inadequate treatment course. This is the first case report identifying the novel use of low-dose lumbar intrathecal ziconotide to...

Cite
Staub BP, Casini GP, Monaco EA, et al. Near-resolution of persistent idiopathic facial pain with low-dose lumbar intrathecal ziconotide: a case report. J Pain Res. 2019;12:945-949doi: 10.2147/JPR.S193746.
Staub, B. P., Casini, G. P., Monaco, E. A., Sekula, R. F., & Emerick, T. D. (2019). Near-resolution of persistent idiopathic facial pain with low-dose lumbar intrathecal ziconotide: a case report. Journal of pain research, 12945-949. https://doi.org/10.2147/JPR.S193746
Staub, Brandon P, et al. "Near-resolution of persistent idiopathic facial pain with low-dose lumbar intrathecal ziconotide: a case report." Journal of pain research vol. 12 (2019): 945-949. doi: https://doi.org/10.2147/JPR.S193746
Staub BP, Casini GP, Monaco EA, Sekula RF, Emerick TD. Near-resolution of persistent idiopathic facial pain with low-dose lumbar intrathecal ziconotide: a case report. J Pain Res. 2019 Mar 08;12:945-949. doi: 10.2147/JPR.S193746. eCollection 2019. PMID: 30881103; PMCID: PMC6413753.
Copy Download .nbib Format: NLM
The inflammatory profile of cerebrospinal fluid, plasma, and saliva from patients with severe neuropathic pain and healthy controls-a pilot study.

BMC neuroscience

Jönsson M, Gerdle B, Ghafouri B, Bäckryd E.
PMID: 33522900
BMC Neurosci. 2021 Feb 01;22(1):6. doi: 10.1186/s12868-021-00608-5.

BACKGROUND: Neuropathic pain (NeuP) is a complex, debilitating condition of the somatosensory system, where dysregulation between pro- and anti-inflammatory cytokines and chemokines are believed to play a pivotal role. As of date, there is no ubiquitously accepted diagnostic test...

Cite
Jönsson M, Gerdle B, Ghafouri B, et al. The inflammatory profile of cerebrospinal fluid, plasma, and saliva from patients with severe neuropathic pain and healthy controls-a pilot study. BMC Neurosci. 2021;22(1):6doi: 10.1186/s12868-021-00608-5.
Jönsson, M., Gerdle, B., Ghafouri, B., & Bäckryd, E. (2021). The inflammatory profile of cerebrospinal fluid, plasma, and saliva from patients with severe neuropathic pain and healthy controls-a pilot study. BMC neuroscience, 22(1), 6. https://doi.org/10.1186/s12868-021-00608-5
Jönsson, Mika, et al. "The inflammatory profile of cerebrospinal fluid, plasma, and saliva from patients with severe neuropathic pain and healthy controls-a pilot study." BMC neuroscience vol. 22,1 (2021): 6. doi: https://doi.org/10.1186/s12868-021-00608-5
Jönsson M, Gerdle B, Ghafouri B, Bäckryd E. The inflammatory profile of cerebrospinal fluid, plasma, and saliva from patients with severe neuropathic pain and healthy controls-a pilot study. BMC Neurosci. 2021 Feb 01;22(1):6. doi: 10.1186/s12868-021-00608-5. PMID: 33522900; PMCID: PMC7852144.
Copy Download .nbib Format: NLM
Neuraxial (epidural and intrathecal) opioids for intractable pain.

British journal of pain

Farquhar-Smith P, Chapman S.
PMID: 26516463
Br J Pain. 2012 Feb;6(1):25-35. doi: 10.1177/2049463712439256.

1. Neuraxial opioids are considered for use in patients who have resistant intractable pain that fails to respond to other treatment options or pain that responds to analgesia but for which the doses required result in unacceptable side-effects. 2....

Cite
Farquhar-Smith P, Chapman S. Neuraxial (epidural and intrathecal) opioids for intractable pain. Br J Pain. 2012;6(1):25-35doi: 10.1177/2049463712439256.
Farquhar-Smith, P., & Chapman, S. (2012). Neuraxial (epidural and intrathecal) opioids for intractable pain. British journal of pain, 6(1), 25-35. https://doi.org/10.1177/2049463712439256
Farquhar-Smith, Paul, and Chapman, Suzanne. "Neuraxial (epidural and intrathecal) opioids for intractable pain." British journal of pain vol. 6,1 (2012): 25-35. doi: https://doi.org/10.1177/2049463712439256
Farquhar-Smith P, Chapman S. Neuraxial (epidural and intrathecal) opioids for intractable pain. Br J Pain. 2012 Feb;6(1):25-35. doi: 10.1177/2049463712439256. PMID: 26516463; PMCID: PMC4590095.
Copy Download .nbib Format: NLM
Exploring the ocean for new drug developments: Marine pharmacology.

Journal of pharmacy & bioallied sciences

Malve H.
PMID: 27134458
J Pharm Bioallied Sci. 2016 Apr-Jun;8(2):83-91. doi: 10.4103/0975-7406.171700.

Disease ailments are changing the patterns, and the new diseases are emerging due to changing environments. The enormous growth of world population has overburdened the existing resources for the drugs. And hence, the drug manufacturers are always on the...

Cite
Malve H. Exploring the ocean for new drug developments: Marine pharmacology. J Pharm Bioallied Sci. 2016;8(2):83-91doi: 10.4103/0975-7406.171700.
Malve, H. (2016). Exploring the ocean for new drug developments: Marine pharmacology. Journal of pharmacy & bioallied sciences, 8(2), 83-91. https://doi.org/10.4103/0975-7406.171700
Malve, Harshad. "Exploring the ocean for new drug developments: Marine pharmacology." Journal of pharmacy & bioallied sciences vol. 8,2 (2016): 83-91. doi: https://doi.org/10.4103/0975-7406.171700
Malve H. Exploring the ocean for new drug developments: Marine pharmacology. J Pharm Bioallied Sci. 2016 Apr-Jun;8(2):83-91. doi: 10.4103/0975-7406.171700. PMID: 27134458; PMCID: PMC4832911.
Copy Download .nbib Format: NLM
Intrathecal pain management: a team-based approach.

Journal of pain research

Adler JA, Lotz NM.
PMID: 29138593
J Pain Res. 2017 Nov 03;10:2565-2575. doi: 10.2147/JPR.S142147. eCollection 2017.

OBJECTIVE: Physician assistants (PAs), nurse practitioners (NPs), and registered nurses (RNs) provide professional services on pain management teams. This review provides an overview of the practical management of chronic pain with intrathecal (IT) therapy using an interprofessional approach (eg,...

Cite
Adler JA, Lotz NM. Intrathecal pain management: a team-based approach. J Pain Res. 2017;10:2565-2575doi: 10.2147/JPR.S142147.
Adler, J. A., & Lotz, N. M. (2017). Intrathecal pain management: a team-based approach. Journal of pain research, 102565-2575. https://doi.org/10.2147/JPR.S142147
Adler, Jeremy A, and Lotz, Neona M. "Intrathecal pain management: a team-based approach." Journal of pain research vol. 10 (2017): 2565-2575. doi: https://doi.org/10.2147/JPR.S142147
Adler JA, Lotz NM. Intrathecal pain management: a team-based approach. J Pain Res. 2017 Nov 03;10:2565-2575. doi: 10.2147/JPR.S142147. eCollection 2017. PMID: 29138593; PMCID: PMC5679690.
Copy Download .nbib Format: NLM
Chronic Pain Management With Ziconotide Induces Suicidal and Homicidal Ideations.

The Annals of pharmacotherapy

Goga JK, Keshishian A, Kutzer D, Walters JK.
PMID: 29557209
Ann Pharmacother. 2018 Jul;52(7):704-705. doi: 10.1177/1060028018765165. Epub 2018 Mar 20.

No abstract available.

Cite
Goga JK, Keshishian A, Kutzer D, et al. Chronic Pain Management With Ziconotide Induces Suicidal and Homicidal Ideations. Ann Pharmacother. 2018;52(7):704-705doi: 10.1177/1060028018765165.
Goga, J. K., Keshishian, A., Kutzer, D., & Walters, J. K. (2018). Chronic Pain Management With Ziconotide Induces Suicidal and Homicidal Ideations. The Annals of pharmacotherapy, 52(7), 704-705. https://doi.org/10.1177/1060028018765165
Goga, Joshana K, et al. "Chronic Pain Management With Ziconotide Induces Suicidal and Homicidal Ideations." The Annals of pharmacotherapy vol. 52,7 (2018): 704-705. doi: https://doi.org/10.1177/1060028018765165
Goga JK, Keshishian A, Kutzer D, Walters JK. Chronic Pain Management With Ziconotide Induces Suicidal and Homicidal Ideations. Ann Pharmacother. 2018 Jul;52(7):704-705. doi: 10.1177/1060028018765165. Epub 2018 Mar 20. PMID: 29557209.
Copy Download .nbib Format: NLM
Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration.

Neuromodulation : journal of the International Neuromodulation Society

Shields D, Montenegro R.
PMID: 22150946
Neuromodulation. 2007 Oct;10:6-11. doi: 10.1111/j.1525-1403.2007.00130.x.

Objective.  To determine the stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal infusion under laboratory conditions at 37°. Materials and Methods.  Admixtures of ziconotide (25 µg/mL) and clonidine hydrochloride (2 mg/mL) with and without...

Cite
Shields D, Montenegro R. Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. Neuromodulation. 2007;10:6-11doi: 10.1111/j.1525-1403.2007.00130.x.
Shields, D., & Montenegro, R. (2007). Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. Neuromodulation : journal of the International Neuromodulation Society, 106-11. https://doi.org/10.1111/j.1525-1403.2007.00130.x
Shields, David, and Montenegro, Rick. "Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration." Neuromodulation : journal of the International Neuromodulation Society vol. 10 (2007): 6-11. doi: https://doi.org/10.1111/j.1525-1403.2007.00130.x
Shields D, Montenegro R. Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. Neuromodulation. 2007 Oct;10:6-11. doi: 10.1111/j.1525-1403.2007.00130.x. PMID: 22150946.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 55 entries